Investment Summary

In February 2017 Revolymer was re-branded as Itaconix. Parkwalk invested in Revolymer in April 2011, and the company successfully raised £25m when it listed on AIM in July 2012 at a small uplift to our original investment level.

Revolymer, spun-out from Bristol University, has 2 core technologies based on amphiphilic polymers & encapsulation which have evolved into 4 platforms leading to multiple uses.

Itaconix is a specialty chemicals business focussed on controlled release, responsive encapsulation systems and delivery systems that improve the functional performance of its customers’ products for home care, personal care, coatings, adhesives, sealants, medicated chewing gum and more.

Itaconix aims to generate significant and growing high quality revenue streams by licensing its unique technologies to manufacturers and marketers within these markets.

In July 2012 Revolymer raised £25.0m on its IPO with Invesco Perpetual buying 28% of the company on listing.